SCHEMBL1104885

SCHEMBL1104885

CCOC(=O)CC(=O)c1cc(Cc2cccc(Cl)c2F)c(OC)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.44
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 3/20 0.41
KDM4E B2RXH2 1/20 0.41
NLRP3 Q96P20 1/20 0.40
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.37
CSF1R P07333 1/20 0.37
EGFR P00533 2/20 0.36
ATM Q13315 1/20 0.36
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
P2RX7 Q99572 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15460009 0.93 KMT2A (0.40) METTL3KMT2AALDH1A1MEN1KDM4E
SCHEMBL4211543 0.93 METTL3 (0.43) METTL3KMT2AALDH1A1MEN1KDM4E
SCHEMBL18627847 0.90 METTL3 (0.43) METTL3KMT2AALDH1A1MEN1KDM4E
SCHEMBL1104896 0.87 METTL3 (0.47) METTL3KMT2AALDH1A1KDM4EPDE3B
SCHEMBL4209881 0.83 METTL3 (0.48) METTL3KMT2AALDH1A1MEN1KDM4E
SCHEMBL4207612 0.83 METTL3 (0.50) METTL3KMT2AALDH1A1KDM4EPDE3B
SCHEMBL16380510 0.83 NLRP3 (0.41) KMT2AALDH1A1MEN1KDM4ENLRP3
SCHEMBL13950806 0.82 METTL3 (0.43) METTL3KMT2AALDH1A1MEN1PDE3B
SCHEMBL1104898 0.82 METTL3 (0.49) METTL3KMT2AALDH1A1KDM4EPDE3B
SCHEMBL1104891 0.82 METTL3 (0.56) METTL3ALDH1A1KDM4EMRGPRX4CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2018-09-20 US disclosed
EP-2880017-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2016-10-05 EP disclosed
EP-2880017-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2016-10-05 EP disclosed
EP-2190804-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2015-11-18 EP disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 EP disclosed
EP-2069280-B1 Process and intermediates for preparing HIV integrase inhibitors GILEAD SCIENCES INC (US) 2015-03-25 EP disclosed
EP-1992607-B1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2014-12-31 EP disclosed
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-04-16 US disclosed
WO-2009036161-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-03-19 WO disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 EP disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 EP disclosed
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-05-29 US disclosed
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-05-29 US disclosed
WO-2008033836-A2 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB METTL3 2511/4885KMT2A 1100/4885ALDH1A1 2138/4885
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885KMT2A 647/4885ALDH1A1 2769/4885
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB METTL3 2511/4885KMT2A 1100/4885ALDH1A1 2138/4885
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 METTL3 938/4885KMT2A 647/4885ALDH1A1 2769/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885KMT2A 647/4885ALDH1A1 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.